Fred Bartlit Jr. told us he fully expected the Second Circuit to deny en banc review of an earlier appellate ruling blessing a pay-to-delay deal involving his client, Bayer. For one thing, the court never asked the defendants to file briefs.

Thanks to a White & Case Freedom of Information Act suit against DOJ, we can now see 100 (redacted) amnesty deals. But whether that's a good thing is a matter of opinion.

Should companies like Expedia and Travelocity pay municipal taxes on the wholesale cost of hotel rooms--or on the price they eventually resell the rooms for? A Texas jury concluded the latter, and hit the travel services with a $20 million tax bill.

For the second time in less than a week, a Delaware Chancery Court judge had harsh words for a CEO seeking to sell his company in a multibillion-dollar deal, but stopped short of blocking the proposed sale.

Weil IP star Matt Powers has taken his lumps in recent weeks for his unsuccessful defense of Microsoft in the Texas trial that resulted in a $290 million verdict against the software giant. But he sure came through for Merck. In an opinion that sent the company's shares soaring, a New Jersey judge barred Teva from introducing a generic version of Merck's allergy blockbuster.

With class certification briefing due next month, BofA may turn out to have been smart for getting out early from this sweeping MDL, which alleges that more than a dozen banks fleeced their most vulnerable depositors by charging exorbitant overdraft fees.